Loading...

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

BACKGROUND: The cure rate for metastatic osteosarcoma has not substantially improved over the past decades. Clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab for metastatic or refractory osteosarcoma were not successful, and neither was immune checkpoint inhibitors (ICIs). METHODS: We...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Hematol Oncol
Main Authors: Park, Jeong A., Cheung, Nai-Kong V.
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2020
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731630/
https://ncbi.nlm.nih.gov/pubmed/33303017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-01012-y
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!